Download Champions' Latest Poster
An Integrated Preclinical Platform for Antibody-Drug Conjugate Development
A data-driven, translational approach to antibody-drug conjugate development.
Antibody-drug conjugates (ADCs) demand precision from discovery through validation. Champions Oncology’s integrated ADC platform bridges target biology, payload optimization, and translational relevance, linking molecular profiling, ex vivo TumorGraft3D assays, and in vivo patient-derived xenograft (PDX) models.Our latest study demonstrates how a multi-omic strategy, coupled with functional validation, identifies tumor-selective ADC targets and refines therapeutic windows across diverse cancer indications.
Key Takeaways
- Target identification through Lumin multi-omics: Integration of transcriptomic and proteomic profiling across >1,500 PDXs and 70+ cancer cell lines.
- Differential expression validation: Comparative analysis of tumor vs. normal tissue using GTEx data to ensure minimal off-target toxicity.
- Functional characterization: Isogenic cell lines and internalization assays confirm target specificity and payload activity.
- Ex vivo efficacy testing: TumorGraft3D organoid models preserve patient tumor heterogeneity, enabling accurate ADC response prediction.
- In vivo confirmation: NK adoptive transfer models evaluate antibody-dependent cellular cytotoxicity (ADCC) under immune-relevant conditions.
- Case example: Identification of “Target-1,” a novel ADC target with limited normal tissue expression and patient-specific response patterns in colorectal PDXs.
- Clinical insight: Variability in ADC sensitivity underscores the importance of matching payload, target, and patient biology early in development.
- Translational advantage: Integrates discovery, validation, and functional testing into one streamlined workflow, accelerating next-generation ADC programs.
- Comprehensive pipeline: From in silico target mining to ex vivo/in vivo efficacy, Champions delivers a complete preclinical continuum.
Download the Poster